3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Recurrence
1
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoglobulin Light-chain Amyloidosis
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Brain Neoplasms
1
Interventions
Melphalan
5
Filgrastim
4
birtamimab
3
Granulocyte Colony-Stimulating Factor
3
Dexamethasone
3
pomalidomide
2
Calcium Dobesilate
2
Bortezomib
2
venetoclax
1
pegfilgrastim
1
nelarabine
1
melflufen
1
daratumumab
1
Tetradecanoylphorbol Acetate
1
Peripheral Blood Stem Cell Transplantation
1
Oxycodone
1
Moxifloxacin
1
Morphine
1
Methadone
1
Fluorescent Antibody Technique
1
Fentanyl
1
Diuretics
1
Ciprofloxacin
1
Blood Component Removal
1
Amoxicillin-Potassium Clavulanate Combination
1
Amifostine
1
4'-deoxy-4'-iododoxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Immunoglobulin Light-chain Amyloidosis
×
Blood Component Removal
×
Clear all
NCT02489500
2018-09-10
VelRand
Boston Medical Center
Phase 3
Terminated
3 enrolled
11 charts